Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

121. ADHD: medication and society

indexing assigned by CRD MeSH Attention Deficit Disorder with Hyperactivitys Language Published English Country of organisation Netherlands English summary An English language summary is available. Address for correspondence Postbus 16052, 2500 BB Den Haag, The Netherlands. Tel: +31 70 340 7520;Fax: +31 70 340 7523 Email: info@gr.nl AccessionNumber 32014000924 Date abstract record published 23/07/2014 Health Technology Assessment (HTA) database Copyright © 2019 Health Council of the Netherlands (...) ADHD: medication and society ADHD: medication and society ADHD: medication and society Health Council of the Netherlands Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Council of the Netherlands. ADHD: medication and society. The Hague: Health Council of the Netherlands Gezondheidsraad (GR). 2014/19. 2014 Final publication URL Indexing Status Subject

2014 Health Technology Assessment (HTA) Database.

122. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. Full Text available with Trip Pro

Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. To investigate the association between drug treatment for attention-deficit/hyperactivity disorder (ADHD) and risk of concomitant suicidal behaviour among patients with ADHD.Register based longitudinal study using within patient design.Linkage of multiple national registers in Sweden.37,936 patients with ADHD born between 1960 and 1996 and followed from 2006 to 2009 for treatment status (...) by ADHD drug treatment and suicide related events (suicide attempt and completed suicide).Incidence rate of suicide related events during ADHD drug treatment periods compared with that during non-treatment periods.Among 37,936 patients with ADHD, 7019 suicide related events occurred during 150,721 person years of follow-up. At the population level, drug treatment of ADHD was associated with an increased rate of suicide related events (hazard ratio 1.31, 95% confidence interval 1.19 to 1.44). However

2014 BMJ

123. Management of ADHD in preschool-aged children

Management of ADHD in preschool-aged children Management of ADHD in preschool-aged children Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Management of ADHD in preschool-aged children View/ Open Date 2013-09 Format Metadata Abstract Behavior therapy interventions, such as parent training, are first-line treatment (...) for ADHD in preschool-aged children (three to five years of age). (Strength of Recommendation [SOR]: B, based on a systematic review of a small number of heterogeneous randomized controlled trials [RCTs].) Medication is an option for children with moderate to severe ADHD if behavior therapy has not been effective and if the benefits outweigh the harms. (SOR: B, based on a systematic review of a small number of heterogeneous RCTs.) Alternative therapies, such as elimination diets, have limited evidence

2014 Clinical Inquiries

124. Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review of the clinical evidence

Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review of the clinical evidence Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review of the clinical evidence Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review (...) of the clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary

2014 Health Technology Assessment (HTA) Database.

125. Abuse and misuse potential of drugs for attention deficit/hyperactivity disorder: a review of the clinical evidence

of this assessment has been made for the HTA database. Citation CADTH. Abuse and misuse potential of drugs for attention deficit/hyperactivity disorder: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions No conclusions can be drawn regarding the abuse potential of atomoxetine due to the limited data available. Misuse of methylphenidate and amphetamine-based ADHD drugs was found (...) Abuse and misuse potential of drugs for attention deficit/hyperactivity disorder: a review of the clinical evidence Abuse and misuse potential of drugs for attention deficit/hyperactivity disorder: a review of the clinical evidence Abuse and misuse potential of drugs for attention deficit/hyperactivity disorder: a review of the clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality

2014 Health Technology Assessment (HTA) Database.

126. Cognitive Behavioral Therapy for Attention Deficit Hyperactivity Disorder (Adults)

Cognitive Behavioral Therapy for Attention Deficit Hyperactivity Disorder (Adults) Cognitive Behavioral Therapy for adult ADHD – Society of Clinical Psychology Description Cognitive behavioral therapy (CBT) for adult ADHD provides concrete strategies and skills for coping with the core symptoms of ADHD (inattention, hyperactivity, impulsivity) and associated impairment in social, occupational, educational, and other domains. Components of CBT for ADHD include psychoeducation, training (...) in organization, planning, and time management, problem solving skills, techniques for reducing distractivity and increasing attention span, and cognitive restructuring particularly around situations that cause distress. Key References (in reverse chronological order) Emilsson, B., Gudjonsson, G., Sigurdsson, J.F., Baldursson, G., Einarsson, E., Olafsdottir, H., & Young, S. (2011). Cognitive behaviour therapy in medicationtreated adults with ADHD and persistent Symptoms: A randomized controlled trial. BMC

2014 Society of Clinical Psychology

127. Systematic review with meta-analysis: Stimulant medication for ADHD not associated with subsequent substance use disorders

not associated with subsequent substance use disorders Paula D Riggs Statistics from Altmetric.com Commentary on: Humphreys KL , Eng T , Lee SS , et al . Stimulant medication and substance use outcomes: a meta-analysis . Context Attention deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric disorders of childhood, affecting 3–7% of school-age children. 1 Stimulant medication is an effective treatment for childhood ADHD and is well established as a first-line treatment in most clinical (...) Systematic review with meta-analysis: Stimulant medication for ADHD not associated with subsequent substance use disorders Stimulant medication for ADHD not associated with subsequent substance use disorders | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password

2014 Evidence-Based Medicine

128. Guanfacine hydrochloride extended release (Intuniv XR ? Shire Canada Inc.) indication: attention deficit hyperactivity disorder

Guanfacine hydrochloride extended release (Intuniv XR ? Shire Canada Inc.) indication: attention deficit hyperactivity disorder Guanfacine hydrochloride extended release (Intuniv XR — Shire Canada Inc.) indication: attention deficit hyperactivity disorder Guanfacine hydrochloride extended release (Intuniv XR — Shire Canada Inc.) indication: attention deficit hyperactivity disorder CADTH Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Guanfacine hydrochloride extended release (Intuniv XR — Shire Canada Inc.) indication: attention deficit hyperactivity disorder. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC Final Recommendation; SR0349. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that guanfacine hydrochloride extended release (GXR) not be listed. Final

2014 Health Technology Assessment (HTA) Database.

129. Atomoxetine is a second-line medication treatment option for ADHD

is already known on this topic? Atomoxetine is a non-stimulant that has no abusive potential and a presynaptic inhibitor of the norepinephrine transporter, and has been found to be a safe and effective treatment for attention deficit/hyperactivity disorder (ADHD) in children, adolescents and adults. 1 What this paper adds? This is the largest meta-analysis of randomised controlled trials of atomoxetine for ADHD. The effect size for atomoxetine versus placebo was higher for medication-naïve youth while (...) factors such as demographic factors, mean dose, etc, did not moderate the treatment response. Limitations Even though atomoxetine improved both inattentive and hyperactive symptoms, response was lower than for stimulants and 40% of participants taking atomoxetine had significant residual ADHD symptoms. Compared with placebo, a higher proportion of those taking atomoxetine had at least one adverse effect, experienced more weight loss and discontinued study participation. Important treatment response

2014 Evidence-Based Mental Health

130. Medication reduces crash risk among men with ADHD Full Text available with Trip Pro

implementation of skills and traits that include attending to the driving task, focusing on relevant hazards, and being aware of traffic and road conditions and responding appropriately. 1 Deficits in attention and impulse control put patients with attention-deficit hyperactivity disorder (ADHD) at increased crash risk. Consistent ADHD medication use, ensuring therapeutic levels while driving, has the potential to reduce this risk. 2 What does this paper add? This landmark population-based study is the first (...) Medication reduces crash risk among men with ADHD Medication reduces crash risk among men with ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search

2014 Evidence-Based Mental Health

131. Autism traits may be more prevalent in ADHD than previously reported

on this topic? Previous research has indicated that there are qualitative and quantitative differences in the behavioural phenotypes of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). 1 The presence of ASD traits in children with ADHD, however, generally portends a more severe profile of symptoms and impairments. Cooper and colleagues’ study is novel due to the very large sample size of children with ADHD, and because it assesses ASD traits on a continuous scale. What (...) Autism traits may be more prevalent in ADHD than previously reported Autism traits may be more prevalent in ADHD than previously reported | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password

2014 Evidence-Based Mental Health

132. Iron Deficiency in Pathophysiology of Attention Deficit Hyperactivity Disorder: A Systematic Review Full Text available with Trip Pro

Iron Deficiency in Pathophysiology of Attention Deficit Hyperactivity Disorder: A Systematic Review dergipark.gov.tr Lütfen https://dergipark.org.tr kullanınız DergiPark bundan 3 yıl önce yeni adresi olan dergipark.org.tr 'ye taşındı. Bu yıl içinde dergipark.gov.tr adresini desteklemeyi bırakmayı planlıyoruz, bu nedenle bağlantılarınızı dergipark.org.tr içerecek şekilde güncellemenizi rica ediyoruz. Please use https://dergipark.org.tr DergiPark moved to its new home at dergipark.org.tr three

2014 Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry

133. Review: recommendations for the assessment and management of sleep disorders in ADHD

Altmetric.com Question Question: What evidence-based or consensus-based recommendations can be made for the assessment and management of sleep problems in children and adolescents with attention deficit hyperactivity disorder (ADHD)? Outcomes: The assessment and management of sleeping problems are as reported. Methods Design: Systematic review. Data sources: PubMed, Ovid, EMBASE and Web of Knowledge were searched for peer-reviewed articles (study type not specified) published up to 31 October 2012. Study (...) Review: recommendations for the assessment and management of sleep disorders in ADHD Review: recommendations for the assessment and management of sleep disorders in ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers

2014 Evidence-Based Mental Health

134. Review: no evidence that stimulant medication for ADHD influences lifetime risk of substance use or dependence

medication for ADHD influences lifetime risk of substance use or dependence Statistics from Altmetric.com Question Question: Does exposure to stimulant medication for attention deficit hyperactivity disorder (ADHD) have an effect on the lifetime risk of substance use or dependence? Outcomes: Lifetime substance use or dependence (alcohol, cocaine, marijuana, nicotine and illicit non-specific drug). Method of assessing substance use/dependence is not reported for included studies. Methods Design (...) Review: no evidence that stimulant medication for ADHD influences lifetime risk of substance use or dependence Review: no evidence that stimulant medication for ADHD influences lifetime risk of substance use or dependence | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username

2014 Evidence-Based Mental Health

135. Clinical practice: Adult attention deficit-hyperactivity disorder. Full Text available with Trip Pro

Clinical practice: Adult attention deficit-hyperactivity disorder. Short-term trials involving adults with ADHD have shown significant improvements in symptoms with stimulants and atomoxetine; however, data on long-term benefits and risks of these medications, particularly among older persons, have been insufficient.

2013 NEJM

136. Tricyclic Antidepressants, Clonidine, Venlafaxine, and Modafinil for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: A Review of the Clinical Evidence

age 43) (cross-over study) Randomized, double- blind, placebo- controlled, cross-over study 6 weeks Improvement in ADHD symptoms measured by the DSM-IV ADHD Behavior Checklist for Adults, the Controlled Oral Word Association Test (COWAT), Stroop and Digit Span Safety (adverse effects) ADHD: attention-deficit/hyperactivity disorder; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders (4 th edition) Tricyclic Antidepressants, Clonidine, Venlafaxine, and Modafinil for ADHD 12 Appendix 3 (...) by the owners’ own terms and conditions. TITLE: Tricyclic Antidepressants, Clonidine, Venlafaxine, and Modafinil for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: A Review of the Clinical Evidence DATE: 21 March 2013 CONTEXT AND POLICY ISSUES Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder with inappropriate levels of inattention, hyperactivity, and impulsivity manifesting in childhood and continuing into adulthood, resulting in functional

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

137. Interventions for Preschool Children at High Risk for ADHD: A Comparative Effectiveness Review (Abstract)

Interventions for Preschool Children at High Risk for ADHD: A Comparative Effectiveness Review The US Agency for Healthcare Research and Quality sponsored a comparative effectiveness review of interventions for preschoolers at risk for attention-deficit/hyperactivity disorder (ADHD).Medline, Cochrane CENTRAL, Embase, PsycInfo, and Education Resources Information Center were searched from 1980 to November 24, 2011. Selected studies were comparative, and enrolled children <6 years with clinically (...) significant disruptive behavior, including ADHD. The interventions evaluated were parent behavior training (PBT), combined home and school/day care interventions, and methylphenidate use. Data were extracted by using customized software. Two independent raters evaluated studies as good, fair, or poor by using the Effective Public Health Practice Project Quality Assessment Tool for Quantitative Studies Risk of Bias. Overall strength of evidence (SOE) was rated for each intervention's effectiveness

2013 EvidenceUpdates

138. Attention-Deficit Hyperactivity Disorder

Attention-Deficit Hyperactivity Disorder 1 Quality Department Guidelines for Clinical Care Ambulatory ADHD Guideline Team Team Leaders John M O'Brien, MD Family Medicine Jennifer G. Christner, MD Child Behavioral Health Team Members Bernard Biermann, MD, PhD Child/Adolescent Psychiatry Barbara T Felt, MD Child Behavioral Health R Van Harrison, PhD Medical Education Paramjeet K Kochhar, MD General Pediatrics Consultant Darcie-Ann Streetman, PharmD College of Pharmacy Initial Release August, 2005 (...) of child’s self-identified impression of function, both strengths and weaknesses • Clinician’s observations of child’s behavior • Physical and neurologic examination Note: From ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents, American Academy of Pediatrics, Nov. 2011 Table 4. Treatment Options for ADHD For pre-school aged children, first line is behavior therapy. If not significantly improved, prescribe

2013 University of Michigan Health System

139. Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate

hyperactivity disorder (ADHD) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate. Lisdexamfetamine dimesylate is a pharmacologically inactive pro-drug that is converted into the central nervous system stimulant, dexamfetamine. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults (NICE guideline CG72, published in 2008) recommends that drug treatment for children and young people (...) with ADHD should always form part of a comprehensive treatment plan that includes psychological, behavioural and educational advice/interventions. It also recommends Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate (ESNM19) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 20that when drug treatment of ADHD is considered appropriate, methylphenidate, atomoxetine

2013 National Institute for Health and Clinical Excellence - Advice

140. Attention deficit hyperactivity disorder in children and young people: clonidine

Behavior Disorders"/ (20051) 22 (hyperactiv* or adhd or "attention deficit").ab,ti. (36749) 23 21 or 22 (42937) Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 26 of 2924 Clonidine/ (12346) 25 (clonidine or clon-ir or clon-xr or catapres).tw. (13055) 26 24 or 25 (16313) 27 23 and 26 (449) 28 14 and 27 (15) 29 19 and 27 (69) 30 28 (...) ), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Clonidine is an alpha 2 -adrenergic agonist that is licensed in the UK for adults to prevent migraine, prevent hot flushing associated with menopause, and treat hypertension. It does not have a UK licence to treat attention deficit hyperactivity disorder (ADHD) in any age group. It is sometimes used off-label (generally as an add-on to a licensed psychostimulant medicine, such as methylphenidate) to treat ADHD

2013 National Institute for Health and Clinical Excellence - Advice